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Abstract
The importance of the results of some large, randomized controlled trials (RCTs) on Hormone
Replacement Therapy (HRT) has modified the risk/benefit perception of HRT. Recent literature
review supports a different management.
The differences in age at initiation and the duration of HRT are key points. HRT appears to
decrease coronary disease in younger women, near menopause; yet, in older women, HRT
increases risk of a coronary event. Although HRT is a recognized method in the prevention and
treatment of osteoporosis, it is not licensed for the prevention of osteoporosis as a first-line
treatment. The effectiveness of low and ultra-low estrogen doses has been demonstrated for the
treatment of vasomotor symptoms, genital atrophy and the prevention of bone loss, with fewer
side-effects than the standard dose therapy. Further research, however, is needed to determine
the effect both on fractures, as well as on cardiovascular and breast diseases. Newer progestins
show effects that are remarkably different from those of other assays. The effectiveness of
testosterone at improving both sexual desire and response in surgically and naturally
postmenopausal women is shown by the testosterone patch.
The intention, dose and regimen of HRT need to be individualized, based on the principle of
choosing the lowest appropriate dose in relation to the severity of symptoms and the time and
menopause age.
Introduction
By 2030, an estimated 47 million women will be under-
going menopause each year [1]. The loss of circulating
estrogens that occurs during the menopausal transition
manifests itself through a variety of symptoms (hot
flushes, night sweats and vaginal atrophy). Approximately
75–80% of women experience menopausal symptoms,
almost half of whom find the symptoms distressing, while
20–30% have severe symptoms [2,3].
For decades, estrogen, either alone or in combination
with progestins, has been the therapy of choice for the
relief of menopausal symptoms, as well as for the longer-
term prevention of postmenopausal osteoporosis [3]. The
results of two large studies on HRT (The Heart and Estro-
gen/progestin Replacement (HERS) Study and the
Women's Health Initiative (WHI) Study), [4,5] [table 1],
however, have modified the risk/benefit perception of
HRT. This situation has been analysed by different scien-
tific societies [6,7] which suggests its use in younger,
recently menopausal women for symptomatic complaints
(vasomotor and vaginal symptoms) and for primary pre-
vention of postmenopausal osteoporosis. Moreover, the
use of lower effective doses of hormones to achieve the
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desired objectives with the appropriate progestin is
another issue. Finally, treatment with androgens for
women with hypoactive sexual desire disorder should be
considered.
Therapeutic window for starting HRT
The literature reveals that a number of studies on the effec-
tiveness of HT have been carried out. Based on more than
40 observational studies of HRT and coronary heart dis-
ease (CHD), the summary relative risk for CHD was
40–50% lower among current or previous users of HT
compared to those who never had used it (p < 0.001) [8].
In 2005 a Cochrane Review demonstrating an absence of
benefit was published [9]. The latter data came from large
prospective studies, such as HERS and WHI, and the
results were consistent in that no benefit in secondary or
primary prevention of cardiovascular disease (CVD)
events was demonstrated.
Key differences between the WHI and observational stud-
ies of HT were the HT initiation and time since meno-
pause [table 1]. The WHI Estrogen + Progestin (E+P) trial
results according to time since menopause were the fol-
lowing: women <10 years since menopause, CHD Rela-
tive Risk (RR) = 0.89; women 10–19 years since
menopause, RR = 1.22; and women 20 years and more
since menopause, RR = 1.71 [10]. The WHI estrogen alone
trial according to age at randomization concluded that the
Myocardial Infarction (MI) or CHD death were the fol-
lowing: aged 50–59 years, RR = 0.63; 60–69 years, RR =
0.94; and 70–79 years, RR = 1.11. The absolute excess risk
by age in the combined trials is completely different
between the 50–59 year-old age group and the other age
groups [table 2] [11]. Consequently, the differences in age
at initiation and the duration of HRT use were sufficient
to explain the discordance betw
een the WHI trial and the observational studies. Further-
more, HRT appears to decrease coronary disease in
younger women, near menopause; yet, in older women,
HRT increases risk of a coronary event.
Bone loss prevention and treatment
At the time of menopause, estrogen deficiency initiates a
rapid loss of Bone Mineral Density (BMD), a decrease of
the micro-architectural deterioration leading to increased
bone fragility and a higher risk of fracture. The results of
the WHI study showed a significant reduction in all frac-
tures in a population of patients who likely did not have
significant fracture risk, based on the Body Mass Index
(BMI), age and BMD results within the sub-group [5,12].
The data from the WHI study are the most robust non-ver-
tebral fracture data extent. Another important aspect of
the study to acknowledge is its quality, because of its sam-
ple size and the length of therapy. This study provides the
largest database of any osteoporosis medication in rand-
omized controlled trials (RCTs).
Although HRT in not licensed anymore for the prevention
of osteoporosis as a first-line treatment, we think that HT
seems to be the only proven effective option for the pri-
mary prevention of postmenopausal osteoporosis. It is a
recognized method in the prevention and treatment of
osteoporosis, which is confirmed by a meta-analysis of
the efficacy of HRT in treating and preventing osteoporo-
sis in postmenopausal women [13].
The lower effective dose
The standard HRT doses, although effective, can be asso-
ciated with adverse effects: breast cancer, venous throm-
boembolism and stroke being the most important.
Several papers have indicated a dose dependency for HRT
[14]. Therefore, it is logical to evaluate the effectiveness,
the tolerability and the adverse effects of low doses of HRT
[15].
Table 2: Absolute risk (cases per 10.000 PYS) by age in the 
combined trials (E+P and E alone) of the WHI
OUTCOME AGE
CHD 50–59 60–69 70–79
TOTAL MORTALITY -2 -1 +19
Modified Rossoux JAMA 2007 -10 -4 +16
Table 1: Key differences between the WHI and observational 
HRT studies
OBSERVATIONAL 
STUDIES
WHI
AGE AT HRT INITIATION
(MEAN)
52 yrs 63 yrs
TIME SINCE MENOPAUSE
(MEAN)
1.5 yrs 12 yrs
VASOMOTOR 
SYMPTOMS
+-
HRT FORMULATIONS DIVERSES CEE+MPA
DURATION OF HRT USE LONG SHORTBMC Women's Health 2008, 8:22 http://www.biomedcentral.com/1472-6874/8/22
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The effectiveness of HRT in the relief of vasomotor symp-
toms in postmenopausal women is well established [16].
Several short-term studies have demonstrated a similar
effectiveness for low doses compared to standard doses in
order to alleviate hot flushes [17,18]. These promising ini-
tial results, suggesting the effectiveness of low doses, were
confirmed by the HOPE study (Women's Health, Oste-
oporosis, Progestin, Estrogen study). This study evaluated
conjugated equine estrogen (CEE) (0.3 or 0.45 mg/d)
combined with medroxyprogesterone acetate MPA (1.5 or
2.5 mg/d). The study demonstrated that low doses were
effective at diminishing the number and the intensity of
hot flushes, and that those low doses seem to be as effec-
tive as the same CEE-MPA association at standard doses
[19].
Other aspects deserve mention. Vasomotor symptoms
appear in several short-term studies which demonstrate
the effectiveness of low doses for the treatment of genital
atrophy. Moreover, the HOPE study, with a larger series,
also demonstrated that low doses are as effective as the
standard ones for improving vaginal atrophy [19]. Still
another aspect is the use of low doses as local treatment
(estrogens for topical vulvo-vaginal administration) [20].
The adverse side effects of these topical treatments are less
than 1/100, the most frequent being mucosa rash or very
light allergic reactions with pruritus. Regarding CVD,
there are few studies in relation to low doses. In a sample
from the HOPE study, the impact of low doses on lipidic
and carbohydrate metabolism were evaluated [21].
Another study concluded that low doses of CEE (0.3 mg/
d) were as effective as the conventional ones (0.625 mg/
d) at improving the lipid profile and the endothelial func-
tion [22].
The major drawback of all these studies are their short
duration and the scant number of subjects included. Con-
sequently, in order to assess the real effect of low doses on
CVD, it is mandatory to design long-term trials which
include a sufficient number of patients.
Bone density and fracture are both related to menopause.
Data from the HOPE study suggest that low doses are
effective at preventing the loss of bone density in spine
and femur and at reducing bone turnover. The administra-
tion of calcium and vitamin D supplements facilitates the
use of a lower dose of estrogen and guarantees an increase
in bone mass in spine and femur similar to that observed
using a standard dose [23]. At present there are no data
correlating low doses and prevention of bone fractures. In
earlier studies, drugs that seemed to reduce fracture inci-
dence based on their effects on bone turnover have turned
out to be really effective at reducing fractures in current
studies [24]. The effect of low doses on bone turnover sug-
gests a similar effect for the prevention of fractures [25].
There are results with a novel, continuous, ultra-low oral
dose combined HRT with estradiol 0.5 mg that can allevi-
ate subjective symptoms providing an effective protection
against the postmenopausal decrease of BMD [26].
Table 3: Comparison of the biological activities of progesterone and drospirenone with other progestogens (28)
Progestogens Biological activities
Progestogenic Androgenic Anti-androgenic Anti-aldosterone Glucocorticoid
Progesterone + - ± + -
Drospirenone + - + + -
Cyproterone acetate + - + - ±
Dienogest + - + - -
Levonorgestrel + ± - - -
Medroxyprogesterone acetate + ± - - ±
Norethisterone + ± - - -
Trimegestone + - ± ± -
Norgestimate + ± - - -
Clinically relevant activity (+); activity not clinically relevant (±); no activity (-)BMC Women's Health 2008, 8:22 http://www.biomedcentral.com/1472-6874/8/22
Page 4 of 5
(page number not for citation purposes)
We can summarize that low dose and ultra-low dose ther-
apies have shown to alleviate menopausal symptoms and
have maintained or improved bone density with fewer
side-effects than standard dose therapy. Nevertheless, fur-
ther research is required to determine what effect the low
and ultra-low dose therapy will have on fracture, cardio-
vascular and breast disease [27]. Consequently, an inter-
esting option may be to begin HRT with low doses in
order to minimize the side effects, and, if the administered
dose eliminates or reduces the subjective symptoms, there
is no reason to increase it.
Appropriate progestin
For many years, progestins were considered as necessary
additions to estrogen to protect the endometrium. How-
ever, while all exert progestagenic activity, they exhibit dif-
ferent patterns of binding at other steroid receptors and,
consequently, display diverse biological activities [28]
[table 3]. Indeed, different progestins may support or
oppose the effects of estrogen, depending on the tissue,
thereby supporting the concept that the clinical selection
of progestins for HRT is critical in determining potential
positive or detrimental effects [29]. Newer progestins,
such as dydrogesterone drospirenone, show effects that
are remarkably different from those of other assays; their
actions might be particularly relevant to the cardiovascu-
lar system and the breast. Overall, it is not possible, given
the profiles of different progestins, to make meaningful
extrapolations from the results for one particular proges-
tin to all progestins as a class nor indeed to all HRT agents
because of their different progestin components [28]
Androgen hormonal therapy
The occurrence in some women of an androgen defi-
ciency, inducing clinical symptoms and target tissue dys-
function, is plausible. Most of the controversy over this
arises from the present difficulty of evaluating androgen
activities in target tissues by using only serum measure-
ments. In fact, the assays used to measure androgens have
not been optimized to measure the low levels found in
women. But there is evidence suggesting that testosterone
might play an important role in different tissues and in
modulating sexual response. The under-production of
androgen in women, as may occur after bilateral
oophorectomy, is associated with reduced sexual desire in
some studies, but not in others [30].
Recently, the EMEA (European Agency for the Evaluation
of Medical Products) approved the testosterone patch as a
therapy for hypoactive sexual desire supported by clinical
trials that show the effectiveness of testosterone at
improving both sexual desire and response in surgically
postmenopausal women. At present we have found five
randomized placebo controlled studies (two phase II
studies and three other phase III studies) with more than
2000 women studied [10]. In four cases, surgical meno-
pause was carried out while in one case there was natural
menopause. In all five cases, the efficacy and safety of a
patch that released 300 μg of testosterone daily were ana-
lyzed [31-35]. All patients were treated with estrogens.
The different results of the questionnaires used showed a
significant increase in sexual desire and sexual response.
In four out of five studies there was a significant reduction
in the distress related to the problem of sexual dysfunc-
tion [31,33,34]. There are certain limitations to the five
studies mentioned here. Only the safety data of the prod-
uct have been evaluated in clinical trials of six months'
duration; at present, there are data for 12 months as phase
III has been prolonged into an open study. It will be nec-
essary, however, to have a long term safety date.
Conclusion
Despite the draw-back in hormone treatment for meno-
pausal women during the last 3–5 years, there has been no
argument about the efficacy and superiority of estrogen as
the treatment of choice for menopausal symptoms. The
recent randomized controlled studies have raised impor-
tant issues that had not been dealt with before, such as the
need to weigh benefits of therapy versus potential risks.
Before treating with HRT, the indication, the balance of
benefit-to-risk, the information given to the patient, and
her acceptance of treatment must be valued. Finally, the
dose and regimen of hormone therapy needs to be indi-
vidualized based on the principle of choosing the lowest
appropriate dose in relation to both severity of symptoms,
as well as menopause age.
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